Importantly, 40% of MTGCSF−/−-bearing mice remained tumor-free for up to 300 days after treatment (Fig. 4B), suggesting that abrogation of tumor-derived GCSF improves adoptive T-cell therapy efficacy. The gene discussed is CSF3; the disease is neoplasm.